Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion type Assertion NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_head.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion description "[The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion evidence source_evidence_literature NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion SIO_000772 22334453 NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion wasDerivedFrom befree-2016 NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.
- NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_assertion wasGeneratedBy ECO_0000203 NP960931.RASlgUrOhsBqQNQ6o9CddQTaF7THzlG0SWMeT8n4AolWQ130_provenance.